Methotrexate Orion (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate. Without tetrahydrofolate, cells cannot synthesize purines and thymidylate, leading to reduced DNA, RNA and protein production. This effect limits the growth of rapidly dividing cells and modulates immune responses.

The specific dose of Methotrexate Orion is determined by the prescribing clinician based on the patient’s condition, weight, renal function and treatment goals. Dosage regimens vary widely across indications and must be individualized by a qualified healthcare professional.

Methotrexate Orion is classified as pregnancy category X, indicating it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended during breastfeeding because it can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Methotrexate Orion belongs to the antimetabolite class, differing from biologic agents that target specific cytokines. It is generally less expensive and administered orally, but may require more laboratory monitoring for liver and blood‑cell effects compared with some newer agents.

Methotrexate Orion tablets should be stored at ambient temperature, below 25 °C, in their original container to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged.

Methotrexate Orion is taken orally, usually with a full glass of water. Depending on the prescribing regimen, it may be taken once weekly or as directed by the healthcare provider. Patients should follow the exact schedule provided by their clinician.

Serious risks include severe liver toxicity, pulmonary fibrosis, and profound bone‑marrow suppression that can lead to infections or bleeding. Regular monitoring of liver enzymes, lung function and blood counts is essential to detect these complications early.

Methotrexate Orion should not be used by pregnant or breastfeeding individuals, patients with severe liver or kidney disease, those with known hypersensitivity to methotrexate, or anyone taking contraindicated medications without medical supervision.